301166 优宁维
已收盘 08-16 15:00:00
资讯
新帖
简况
A股午后猴痘概念持续拉升,海辰药业、亚太药业2连板,透景生命、普利制药、合富中国涨停,博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。
美港电讯 · 08-16 13:44
A股午后猴痘概念持续拉升,海辰药业、亚太药业2连板,透景生命、普利制药、合富中国涨停,博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。
优宁维(301166)8月15日主力资金净买入125.75万元
证券之星 · 08-16 09:12
优宁维(301166)8月15日主力资金净买入125.75万元
【猴痘概念板块活跃,海辰药业、亚太药业涨停 公司回应来了】金十数据8月15日讯,猴痘概念板块活跃,海辰药业、亚太药业涨停,博晖创新、优宁维、万泰生物等涨超4%。
美港电讯 · 08-15 16:57
【猴痘概念板块活跃,海辰药业、亚太药业涨停 公司回应来了】金十数据8月15日讯,猴痘概念板块活跃,海辰药业、亚太药业涨停,博晖创新、优宁维、万泰生物等涨超4%。
【优宁维:公司猴痘体外检测产品主要用于科研 在国内外没有获批】金十数据8月15日讯,从优宁维证券部获悉,公司猴痘体外检测产品主要是科研用途,用量不大,目前在国内外尚未获批。
美港电讯 · 08-15 12:30
【优宁维:公司猴痘体外检测产品主要用于科研 在国内外没有获批】金十数据8月15日讯,从优宁维证券部获悉,公司猴痘体外检测产品主要是科研用途,用量不大,目前在国内外尚未获批。
A股猴痘概念股开盘大涨,海辰药业、亚太药业涨停,西点药业、博晖创新涨超10%,凯普生物、优宁维、达安基因等均大幅高开。
美港电讯 · 08-15 09:28
A股猴痘概念股开盘大涨,海辰药业、亚太药业涨停,西点药业、博晖创新涨超10%,凯普生物、优宁维、达安基因等均大幅高开。
优宁维(301166)8月13日主力资金净卖出335.43万元
证券之星 · 08-14
优宁维(301166)8月13日主力资金净卖出335.43万元
优宁维(301166)8月9日主力资金净买入201.13万元
证券之星 · 08-12
优宁维(301166)8月9日主力资金净买入201.13万元
猴痘概念盘中拉升,优宁维涨7.76%
自选股智能写手 · 08-09
猴痘概念盘中拉升,优宁维涨7.76%
A股异动丨优宁维跌近4% 股东泰礼投资和含泰投资拟合计减持不超2%优宁维(301166.SZ)现跌3.79%报26.66元。
格隆汇 · 08-05
A股异动丨优宁维跌近4% 股东泰礼投资和含泰投资拟合计减持不超2%优宁维(301166.SZ)现跌3.79%报26.66元。
优宁维:持股8.51%股东泰礼投资和含泰投资计划3个月内减持不超过2%。
华尔街见闻 · 08-02
优宁维:持股8.51%股东泰礼投资和含泰投资计划3个月内减持不超过2%。
【优宁维(301166.SZ)股东泰礼投资和含泰投资拟合计减持不超172.75万股】智通财经APP讯,优宁维(301166.
智通财经 · 08-02
【优宁维(301166.SZ)股东泰礼投资和含泰投资拟合计减持不超172.75万股】智通财经APP讯,优宁维(301166.
优宁维(301166.SZ)股东泰礼投资和含泰投资拟合计减持不超172.75万股
智通财经 · 08-02
优宁维(301166.SZ)股东泰礼投资和含泰投资拟合计减持不超172.75万股
优宁维最新公告:股东泰礼投资和含泰投资计划合计减持不超过2%
证券之星 · 08-02
优宁维最新公告:股东泰礼投资和含泰投资计划合计减持不超过2%
优宁维:股东泰礼投资和含泰投资计划合计减持不超过2%优宁维公告,公司股东泰礼投资和含泰投资计划自本公告披露之日起15个交易日后的3个月内,通过集中竞价或大宗交易的方式合计减持不超过172.
格隆汇 · 08-02
优宁维:股东泰礼投资和含泰投资计划合计减持不超过2%优宁维公告,公司股东泰礼投资和含泰投资计划自本公告披露之日起15个交易日后的3个月内,通过集中竞价或大宗交易的方式合计减持不超过172.
优宁维:根据证监会关于所属行业的划分,公司在上市之初被认定为批发业
证券之星 · 07-26
优宁维:根据证监会关于所属行业的划分,公司在上市之初被认定为批发业
优宁维:南京优宁维承建的“南京生物制剂生产线建设项目”尚处于建设过程中,目前处于建设后期
证券之星 · 07-15
优宁维:南京优宁维承建的“南京生物制剂生产线建设项目”尚处于建设过程中,目前处于建设后期
千金藤素概念盘中拉升,优宁维涨1.54%
自选股智能写手 · 07-05
千金藤素概念盘中拉升,优宁维涨1.54%
优宁维(301166)6月28日主力资金净买入202.04万元
证券之星 · 07-01
优宁维(301166)6月28日主力资金净买入202.04万元
优宁维(301166)6月26日主力资金净卖出281.07万元
证券之星 · 06-27
优宁维(301166)6月26日主力资金净卖出281.07万元
优宁维:6月25日高管冷兆文增持股份合计1000股
证券之星 · 06-26
优宁维:6月25日高管冷兆文增持股份合计1000股
加载更多
公司概况
公司名称:
上海优宁维生物科技股份有限公司
所属行业:
批发业
上市日期:
2021-12-28
主营业务:
上海优宁维生物科技股份有限公司是一家面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务的科学服务商。公司主要产品及服务有生命科学试剂、生命科学仪器及耗材、综合技术服务。目前公司提供生命科学产品SKU约870万种,覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象,涵盖生命科学基础研究、医学基础研究、体外诊断研究、药物研发、细胞治疗研究等领域,是国内生命科学产品种类及规格最全面的供应商之一。
发行价格:
86.06
{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":31.35,"timestamp":1723791780000,"preClose":29.03,"halted":0,"volume":6048060,"delay":0,"floatShares":41268900,"shares":86666700,"eps":0.3185,"marketStatus":"已收盘","marketStatusCode":5,"change":2.32,"latestTime":"08-16 15:00:00","open":28.85,"high":32.38,"low":28.23,"amount":185000000,"amplitude":0.143,"askPrice":31.36,"askSize":384,"bidPrice":31.35,"bidSize":170,"shortable":0,"etf":0,"ttmEps":0.3185,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724031000000},"adr":0,"adjPreClose":29.03,"symbolType":"stock","openAndCloseTimeList":[[1723771800000,1723779000000],[1723784400000,1723791600000]],"highLimit":31.93,"lowLimit":26.13,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86666668,"pbRate":1.19,"roa":"--","roe":"0.02%","epsLYR":0.47,"committee":-0.393387,"marketValue":2717000000,"floatMarketCap":1294000000,"peRate":98.430138,"changeRate":0.0799,"turnoverRate":0.1466,"status":0},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2459522952","title":"A股午后猴痘概念持续拉升,海辰药业、亚太药业2连板,透景生命、普利制药、合富中国涨停,博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459522952","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459522952?lang=zh_cn&edition=full","pubTime":"2024-08-16 13:44","pubTimestamp":1723787075,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0012","300318","300642","301166","BK0250","300584","BK0048","002370","BK0132","399300","688317","300630","BK0028","BK0042","BK0239","BK0046","BK0251","603122","159982","300463"],"gpt_icon":0},{"id":"2459235465","title":"优宁维(301166)8月15日主力资金净买入125.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459235465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459235465?lang=zh_cn&edition=full","pubTime":"2024-08-16 09:12","pubTimestamp":1723770730,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月15日收盘,优宁维报收于29.03元,上涨5.76%,换手率7.55%,成交量3.11万手,成交额9085.98万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入700.44万元,融资偿还628.69万元,融资净买入71.75万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600014752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2459417039","title":"【猴痘概念板块活跃,海辰药业、亚太药业涨停 公司回应来了】金十数据8月15日讯,猴痘概念板块活跃,海辰药业、亚太药业涨停,博晖创新、优宁维、万泰生物等涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459417039","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459417039?lang=zh_cn&edition=full","pubTime":"2024-08-15 16:57","pubTimestamp":1723712244,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0132","300318","BK1200","LU1981816686.USD","BK0251","BK1589","301166","002370","BK0250","BK0048","BK0028","09633","300584","603392","BK0239"],"gpt_icon":0},{"id":"2459949339","title":"【优宁维:公司猴痘体外检测产品主要用于科研 在国内外没有获批】金十数据8月15日讯,从优宁维证券部获悉,公司猴痘体外检测产品主要是科研用途,用量不大,目前在国内外尚未获批。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459949339","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459949339?lang=zh_cn&edition=full","pubTime":"2024-08-15 12:30","pubTimestamp":1723696209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2459045717","title":"A股猴痘概念股开盘大涨,海辰药业、亚太药业涨停,西点药业、博晖创新涨超10%,凯普生物、优宁维、达安基因等均大幅高开。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459045717","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459045717?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:28","pubTimestamp":1723685304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159982","301130","BK0046","300318","BK0048","BK0122","BK0188","BK0159","BK0250","301166","BK0028","BK0239","002030","BK0168","BK0251","BK0042","BK0132","300639","002370","300584","399300"],"gpt_icon":0},{"id":"2459049169","title":"优宁维(301166)8月13日主力资金净卖出335.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459049169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459049169?lang=zh_cn&edition=full","pubTime":"2024-08-14 09:22","pubTimestamp":1723598535,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月13日收盘,优宁维报收于27.65元,下跌3.46%,换手率4.54%,成交量1.87万手,成交额5121.13万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入297.19万元,融资偿还377.96万元,融资净偿还80.77万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400016496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2458264894","title":"优宁维(301166)8月9日主力资金净买入201.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458264894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458264894?lang=zh_cn&edition=full","pubTime":"2024-08-12 09:12","pubTimestamp":1723425162,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月9日收盘,优宁维报收于28.37元,上涨3.35%,换手率5.75%,成交量2.37万手,成交额6694.3万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入438.61万元,融资偿还506.65万元,融资净偿还68.04万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200002386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2458587168","title":"猴痘概念盘中拉升,优宁维涨7.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458587168","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458587168?lang=zh_cn&edition=full","pubTime":"2024-08-09 13:05","pubTimestamp":1723179942,"startTime":"0","endTime":"0","summary":"08月09日,猴痘概念盘中拉升,截至13点05分,猴痘概念整体指数上涨0.51%,报772.260点。从个股上来看,该概念的成分股中,优宁维涨7.76%,之江生物、西点药业、润达医疗涨幅居前。从资金上来看,截止发稿,猴痘概念主力净流入为-8805.73万,其中润达医疗受到资金热捧,主力净流入2273.56万;拉长时间线来看,该板块近20日主力资金净流入-10.95亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809130542aefe0ecf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809130542aefe0ecf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603108","301166","BK0250"],"gpt_icon":0},{"id":"2457158237","title":"A股异动丨优宁维跌近4% 股东泰礼投资和含泰投资拟合计减持不超2%优宁维(301166.SZ)现跌3.79%报26.66元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457158237","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457158237?lang=zh_cn&edition=full","pubTime":"2024-08-05 14:25","pubTimestamp":1722839157,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159982","BK0250","399300","301166"],"gpt_icon":0},{"id":"2456886402","title":"优宁维:持股8.51%股东泰礼投资和含泰投资计划3个月内减持不超过2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456886402","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456886402?lang=zh_cn&edition=full","pubTime":"2024-08-02 19:50","pubTimestamp":1722599432,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2456761404","title":"【优宁维(301166.SZ)股东泰礼投资和含泰投资拟合计减持不超172.75万股】智通财经APP讯,优宁维(301166.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456761404","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456761404?lang=zh_cn&edition=full","pubTime":"2024-08-02 19:39","pubTimestamp":1722598769,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2456404169","title":"优宁维(301166.SZ)股东泰礼投资和含泰投资拟合计减持不超172.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2456404169","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456404169?lang=zh_cn&edition=full","pubTime":"2024-08-02 19:39","pubTimestamp":1722598769,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)公告,公司股东泰礼投资和含泰投资拟通过集中竞价或大宗交易的方式合计减持不超过172.75万股公司股份,减持比例不超过公司扣除回购专户股份后总股本的2.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1159509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2456404488","title":"优宁维最新公告:股东泰礼投资和含泰投资计划合计减持不超过2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2456404488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456404488?lang=zh_cn&edition=full","pubTime":"2024-08-02 19:29","pubTimestamp":1722598190,"startTime":"0","endTime":"0","summary":"优宁维公告,公司股东泰礼投资和含泰投资计划自本公告披露之日起15个交易日后的3个月内,通过集中竞价或大宗交易的方式合计减持不超过172.75万股公司股份,减持比例不超过公司扣除回购专户股份后总股本的2%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080200044149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2456011774","title":"优宁维:股东泰礼投资和含泰投资计划合计减持不超过2%优宁维公告,公司股东泰礼投资和含泰投资计划自本公告披露之日起15个交易日后的3个月内,通过集中竞价或大宗交易的方式合计减持不超过172.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456011774","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456011774?lang=zh_cn&edition=full","pubTime":"2024-08-02 19:28","pubTimestamp":1722598130,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2454318488","title":"优宁维:根据证监会关于所属行业的划分,公司在上市之初被认定为批发业","url":"https://stock-news.laohu8.com/highlight/detail?id=2454318488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454318488?lang=zh_cn&edition=full","pubTime":"2024-07-26 17:04","pubTimestamp":1721984683,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维07月26日在投资者关系平台上答复投资者关心的问题。公司下属子公司爱必信(上海)生物科技有限公司及孙公司上海云焱软件科技有限公司属于高新技术企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072600035116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2451619339","title":"优宁维:南京优宁维承建的“南京生物制剂生产线建设项目”尚处于建设过程中,目前处于建设后期","url":"https://stock-news.laohu8.com/highlight/detail?id=2451619339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451619339?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:04","pubTimestamp":1721034247,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维07月15日在投资者关系平台上答复投资者关心的问题。南京优宁维承建的“南京生物制剂生产线建设项目”尚处于建设过程中,目前处于建设后期。项目建设进程可关注公司后续披露的相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500022778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2449400853","title":"千金藤素概念盘中拉升,优宁维涨1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449400853","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449400853?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:44","pubTimestamp":1720143873,"startTime":"0","endTime":"0","summary":"07月05日,千金藤素概念盘中拉升,截至09点44分,千金藤素概念整体指数上涨0.54%,报703.200点。从个股上来看,该概念的成分股中,优宁维涨1.54%,方盛制药、理邦仪器、皓元医药涨幅居前。从资金上来看,截止发稿,千金藤素概念主力净流入为-538.61万,其中皓元医药受到资金热捧,主力净流入70.17万;拉长时间线来看,该板块近20日主力资金净流入-4.20亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705094433941f402e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705094433941f402e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688131","BK0250","301166","BK0216"],"gpt_icon":0},{"id":"2448933176","title":"优宁维(301166)6月28日主力资金净买入202.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448933176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448933176?lang=zh_cn&edition=full","pubTime":"2024-07-01 09:22","pubTimestamp":1719796920,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月28日收盘,优宁维报收于27.0元,下跌2.42%,换手率2.65%,成交量1.09万手,成交额3005.99万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入523.61万元,融资偿还180.13万元,融资净买入343.49万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100003709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2446321814","title":"优宁维(301166)6月26日主力资金净卖出281.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446321814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446321814?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:13","pubTimestamp":1719450791,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月26日收盘,优宁维报收于28.52元,上涨7.7%,换手率5.1%,成交量2.1万手,成交额6054.36万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入430.69万元,融资偿还631.97万元,融资净偿还201.29万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700013438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2446393528","title":"优宁维:6月25日高管冷兆文增持股份合计1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446393528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446393528?lang=zh_cn&edition=full","pubTime":"2024-06-26 21:01","pubTimestamp":1719406897,"startTime":"0","endTime":"0","summary":"证券之星消息,根据6月26日市场公开信息、上市公司公告及交易所披露数据整理,优宁维最新董监高及相关人员股份变动情况:2024年6月25日公司董事冷兆文共增持公司股份1000.0股,占公司总股本为0.0012%。变动期间公司股价下跌0.3%,6月25日当日收盘报26.48元。优宁维近半年内的董监高及核心技术人员增减持详情如下:优宁维的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入71.46万,融资余额增加;融券净流入200.0,融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600042244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","stockEarnings":[{"period":"1week","weight":0.105},{"period":"1month","weight":0.1989},{"period":"3month","weight":0.0375},{"period":"6month","weight":0.1952},{"period":"1year","weight":-0.2696},{"period":"ytd","weight":-0.171}],"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","perCapita":"3527股","boardName":"批发业","registeredCapital":"8666万元","compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0282},{"period":"3month","weight":-0.0871},{"period":"6month","weight":0.0047},{"period":"1year","weight":-0.0899},{"period":"ytd","weight":-0.0321}],"survey":" 上海优宁维生物科技股份有限公司是一家面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务的科学服务商。公司主要产品及服务有生命科学试剂、生命科学仪器及耗材、综合技术服务。目前公司提供生命科学产品SKU约870万种,覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象,涵盖生命科学基础研究、医学基础研究、体外诊断研究、药物研发、细胞治疗研究等领域,是国内生命科学产品种类及规格最全面的供应商之一。","serverTime":1723938787009,"listedPrice":86.06,"stockholders":"11700人(较上一季度减少8.91%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}